1778
PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.
 A 34-year-old woman with chronic hepatitis C, genotype 3: Subject; 34-year-old: Subject.Age; woman: Subject.Gender; genotype 3: Subject.Disorder; progressive malaise and anemia: Effect; pegylated interferon alpha-2a and ribavirin for 6 months: Treatment; 6 months: Treatment.Duration; pegylated interferon alpha-2a: Treatment.Drug; ribavirin: Treatment.Drug; 6 months: Treatment.Time_elapsed; chronic hepatitis C: Treatment.Disorder; ribavirin: Combination.Drug; pegylated interferon alpha-2a: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 A 34-year-old woman with chronic hepatitis C, genotype 3: Subject; 34-year-old: Subject.Age; woman: Subject.Gender; genotype 3: Subject.Disorder; progressive malaise and anemia: Effect; pegylated interferon alpha-2a and ribavirin for 6 months: Treatment; 6 months: Treatment.Duration; pegylated interferon alpha-2a: Treatment.Drug; ribavirin: Treatment.Drug; 6 months: Treatment.Time_elapsed; chronic hepatitis C: Treatment.Disorder; ribavirin: Combination.Drug; pegylated interferon alpha-2a: Combination.Drug